URUri Rimon

Uri Rimon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Uri Rimon has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment of renal angiomyolipoma: pooled analysis of individual patient data

    by Teele Kuusk, Fausto Biancari, Brian Lane, Conrad Tobert, Steven Campbell, Uri Rimon, Vito D’andrea, Aare Mehik, Markku H. Vaarala

    This study was performed to evaluate the impact of baseline characteristics and treatment methods on the outcome of sporadic renal angiomyolipoma (AML). This was a pooled analysis of individual data of 441 patients with AML retrieved from 58 studies and 3 institutional series. Ninety-three patients underwent nephrectomy, 163 partial nephrectomy/enucleation, 128 embolisation, 19 cryoablation, 6 radiofrequency ablation, and 32 conservative treatment. Their mean follow-up period was 44.5 months. Patients who experienced major bleeding at presentation had significantly larger tumours than did those without bleeding (mean diameter, 10.1 vs. 5.9 cm, respectively; p < 0.0001). A total of 9.4 % and 26.4 % of bleeding tumours had a diameter of <4 and <6 cm, respectively. A tumour diameter of ≥8.0 cm (hazard ratio, 2.07; 95 % confidence interval, 1.20–4.77) and the treatment method (p = 0.001) were independent predictors of re-intervention. The risk of re-intervention was significantly higher after embolisation, particularly for large tumours (5-year rate of freedom from re-intervention: diameter of ≥8.0 cm, 49.2 %; diameter of 6 cm. These results suggest that conservative treatment can be considered in AMLs of <6 cm in diameter. Among current treatment methods, embolisation was associated with a significantly higher risk of re-intervention. Further studies are needed to define risk factors for bleeding and assess the relative benefits of different treatment modalities.


  • Osteoid osteoma—the CT vessel sign

    by Gal Yaniv, Noga Shabshin, Michal Sharon, Boaz Liberman, Alex Garniack, Uri Rimon, Iris Eshed

    Objective To evaluate whether the presence of a feeding vessel in proximity to osteoid osteomas of long bones on multidetector CT (MDCT) can be an adjuvant clue for the diagnosis of osteoid osteoma. Materials and methods Forty-nine CT scans of patients with radiological and clinical diagnosis of osteoid osteoma of long bones and a control group of 20 CT scans of patients with cortical-based lesions other then osteoid osteoma were analyzed. Two radiologists evaluated the CT images in consensus for the presence of a blood vessel in the same axial slices in which the nidus of osteoid osteoma was seen and to determine the incidence. Results In 39 cases (79.6%) of osteoid osteoma, a blood vessel either entered the nidus (23 patients) or was seen in proximity to it (16 patients). This was significantly different (P < 0.05) from the cortical-based lesions, in which only two CT scans (10%) showed a blood vessel in the lesion’s proximity. Conclusion In the majority of osteoid osteoma lesions in long bones, a blood vessel can be seen on MDCT either entering the nidus itself or in its proximity. The role of this vessel in the lesion pathogenesis and whether it improves diagnostic accuracy need further evaluation.